-
51.
公开(公告)号:US20190002392A1
公开(公告)日:2019-01-03
申请号:US16062152
申请日:2016-12-12
发明人: Bruno DELFORT , Julien GRANDJEAN
IPC分类号: C07C213/04 , C07C213/08 , C07C215/14 , C07C231/02 , C07C233/05 , C07C235/08 , C07C209/50 , C07C209/16 , C07C211/12
摘要: The invention relates to a synthesis method for at least one nitrogen compound belonging to the family of partly N-hydroxyethylated tertiary 1,6-hexanediamines with general formula (I) as follows: wherein radicals R1, R2, R3 are each selected indiscriminately among a methyl radical and a hydroxyethyl radical, and at least one radical among R1, R2, R3 is a methyl radical, comprising at least a first reaction between a first halogen atom-free precursor compound and a second halogen atom-free precursor compound. The first precursor compound comprises a carbon skeleton consisting of a linear sequence of 6 carbon atoms with the 4 central carbon atoms bonded each to 2 hydrogen atoms and the carbon atoms in alpha and omega position not bonded to a halogen atom.
-
公开(公告)号:US09707205B2
公开(公告)日:2017-07-18
申请号:US14920780
申请日:2015-10-22
发明人: Gurmit S. Gill , Damian W. Grobelny
IPC分类号: A61K31/00 , A61K31/343 , A61K31/16 , A61K31/18 , A61K31/382 , A61K31/397 , A61K31/403 , A61K31/41 , A61K31/4164 , C07C33/26 , C07C215/10 , C07C215/14 , C07C215/16 , C07C229/16 , C07C275/24 , C07C275/28 , C07C281/06 , C07D205/04 , C07D209/04 , C07D209/08 , C07D215/18 , C07D233/32 , C07D241/12 , C07D257/04 , C07D295/104 , C07D307/79 , C07D307/81 , C07D311/22 , C07D333/04 , C07D333/20 , C07D413/10 , C07D413/14 , C07F9/09 , C07F9/6558 , C07D413/04 , A61K31/4245
CPC分类号: A61K31/343 , A61K31/16 , A61K31/18 , A61K31/382 , A61K31/397 , A61K31/403 , A61K31/41 , A61K31/4164 , A61K31/4245 , C07C33/26 , C07C215/10 , C07C215/14 , C07C215/16 , C07C229/16 , C07C275/24 , C07C275/28 , C07C281/06 , C07C2602/42 , C07C2603/74 , C07D205/04 , C07D209/04 , C07D209/08 , C07D215/18 , C07D233/32 , C07D241/12 , C07D257/04 , C07D295/104 , C07D307/79 , C07D307/81 , C07D311/22 , C07D333/04 , C07D333/20 , C07D413/04 , C07D413/10 , C07D413/14 , C07F9/094 , C07F9/65586 , Y02A50/402 , Y02A50/47
摘要: The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.
-
公开(公告)号:US09691517B2
公开(公告)日:2017-06-27
申请号:US14701837
申请日:2015-05-01
IPC分类号: H01B1/12 , C08G18/32 , C07C215/10 , C07C215/12 , C07C215/14 , C07C215/18 , C07C311/09 , C07C311/32 , C08G18/48 , C08G18/08 , C07C215/40 , C07D213/04 , C07D207/06 , C07C217/08 , C07D285/15 , C07D233/61 , C07C311/48 , C08G18/38 , C08G18/76
CPC分类号: H01B1/122 , C07C215/10 , C07C215/12 , C07C215/14 , C07C215/18 , C07C215/40 , C07C217/08 , C07C311/09 , C07C311/32 , C07C311/48 , C07D207/06 , C07D213/04 , C07D233/61 , C07D285/15 , C08G18/0814 , C08G18/3275 , C08G18/3278 , C08G18/3281 , C08G18/3284 , C08G18/3861 , C08G18/48 , C08G18/7671 , H01B1/125
摘要: Provided are a hydroxy compound and an ion conducting agent each having excellent electroconductivity. Also provided is an electroconductive resin composition suppressed in bleeding and excellent in electroconductivity through the use of the hydroxy compound. Specifically, provided are a hydroxy compound represented by the following general formula (1), and an ion conducting agent including the hydroxy compound.
-
54.
公开(公告)号:US09604900B2
公开(公告)日:2017-03-28
申请号:US14111157
申请日:2012-04-13
IPC分类号: A01N43/16 , A61K31/35 , C07D311/00 , C07C57/38 , C07C59/66 , C07D215/14 , C07D311/58 , C07D405/04 , C07D407/04 , A61K31/192 , A61K31/352 , A61K31/473 , C07C215/14 , A61K31/353 , A61K31/357 , A61K31/47 , A61K31/4709 , A61K31/553 , A61K45/06 , C07D215/54 , C07D311/74 , C07D413/04
CPC分类号: C07C57/38 , A61K31/192 , A61K31/352 , A61K31/353 , A61K31/357 , A61K31/47 , A61K31/4709 , A61K31/473 , A61K31/553 , A61K45/06 , C07C59/66 , C07C215/14 , C07D215/14 , C07D215/54 , C07D311/58 , C07D311/74 , C07D405/04 , C07D407/04 , C07D413/04
摘要: The present invention relates to aromatic carbocycle or heterocycle compounds comprising an acid function and being of formula (5), wherein W, Q1, Q2, Q3, Q4, R1, R3, R4, R7, R9, R11, a, c, e, and g are as described in the description; and the use of such compounds in the treatment or the prevention of viral disorders, including HIV.
-
公开(公告)号:US09403767B2
公开(公告)日:2016-08-02
申请号:US13803295
申请日:2013-03-14
申请人: Grünenthal GmbH
发明人: Bert Nolte , Wolfgang Schröder , Klaus Linz , Werner Englberger , Hans Schick , Heinz Graubaum , Birgit Braun , Sigrid Ozegowski , József Bálint , Helmut Sonnenschein
IPC分类号: C07C211/00 , C07D209/20 , C07C211/40 , C07C215/14 , C07C215/42 , C07C217/74 , C07C223/04 , C07C229/16 , C07C233/36 , C07C233/40 , C07C233/41 , C07C233/62 , C07C233/79 , C07C235/54 , C07C237/06 , C07C275/24 , C07C311/07 , C07C311/18 , C07D209/12 , C07D209/14 , C07D211/62 , C07D213/12 , C07D213/82 , C07D231/14 , C07D251/54 , C07D295/135 , C07D309/08 , C07D333/20 , C07D403/08 , C07D409/08 , A61K31/135 , A61K45/06 , A61K31/136 , A61K31/165 , A61K31/18 , A61K31/404 , A61K31/53 , A61K31/5377 , C07C211/54 , C07C237/24 , C07C311/37 , C07D251/48
CPC分类号: C07D209/20 , A61K31/135 , A61K31/136 , A61K31/165 , A61K31/18 , A61K31/404 , A61K31/53 , A61K31/5377 , A61K45/06 , C07C211/40 , C07C211/54 , C07C215/14 , C07C215/42 , C07C217/74 , C07C223/04 , C07C229/16 , C07C233/36 , C07C233/40 , C07C233/41 , C07C233/62 , C07C233/79 , C07C235/54 , C07C237/06 , C07C237/24 , C07C275/24 , C07C311/07 , C07C311/18 , C07C311/37 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07D209/12 , C07D209/14 , C07D211/62 , C07D213/12 , C07D213/82 , C07D231/14 , C07D251/48 , C07D251/54 , C07D295/135 , C07D309/08 , C07D333/20 , C07D403/08 , C07D409/08
摘要: The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.
摘要翻译: 本发明涉及对μ-阿片受体和ORL1-受体具有亲和力的化合物,其生产方法,含有这些化合物的药物以及这些化合物用于治疗疼痛和其它病症的用途。
-
公开(公告)号:US09193716B2
公开(公告)日:2015-11-24
申请号:US14066276
申请日:2013-10-29
发明人: Gurmit S. Gill , Damian W. Grobelny
IPC分类号: A61K31/00 , C07D413/04 , A61K31/16 , A61K31/18 , A61K31/343 , A61K31/382 , A61K31/397 , A61K31/403 , A61K31/41 , A61K31/4164 , C07C33/26 , C07C215/10 , C07C215/14 , C07C215/16 , C07C229/16 , C07C275/24 , C07C275/28 , C07C281/06 , C07D205/04 , C07D209/04 , C07D209/08 , C07D215/18 , C07D233/32 , C07D241/12 , C07D257/04 , C07D295/104 , C07D307/79 , C07D307/81 , C07D311/22 , C07D333/04 , C07D333/20 , C07D413/10 , C07D413/14 , C07F9/09 , C07F9/6558
CPC分类号: A61K31/343 , A61K31/16 , A61K31/18 , A61K31/382 , A61K31/397 , A61K31/403 , A61K31/41 , A61K31/4164 , A61K31/4245 , C07C33/26 , C07C215/10 , C07C215/14 , C07C215/16 , C07C229/16 , C07C275/24 , C07C275/28 , C07C281/06 , C07C2602/42 , C07C2603/74 , C07D205/04 , C07D209/04 , C07D209/08 , C07D215/18 , C07D233/32 , C07D241/12 , C07D257/04 , C07D295/104 , C07D307/79 , C07D307/81 , C07D311/22 , C07D333/04 , C07D333/20 , C07D413/04 , C07D413/10 , C07D413/14 , C07F9/094 , C07F9/65586 , Y02A50/402 , Y02A50/47
摘要: The invention relates to novel compounds that have SIP receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate SIP receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate SIP receptor modulating activity or expression such as autoimmune response.
摘要翻译: 本发明涉及具有SIP受体调节活性的新化合物。 此外,本发明涉及包含至少一种本发明化合物的药物,其用于治疗由不适当的SIP受体调节活性或表达引起或与之相关的疾病和/或症状,例如自身免疫应答。 本发明的另一方面涉及包含至少一种本发明化合物的药物在制备用于治疗由不适当的SIP受体调节活性或表达引起或与之相关的疾病和/或症状的药物的用途,例如 自身免疫反应。
-
公开(公告)号:US20050014962A1
公开(公告)日:2005-01-20
申请号:US10851658
申请日:2004-05-24
申请人: Gulilat Gebeyehu , Taysir Jaouni , Joel Jessee
发明人: Gulilat Gebeyehu , Taysir Jaouni , Joel Jessee
IPC分类号: A61K20060101 , C07C215/14 , C07C217/28 , C07F9/02
CPC分类号: C07C217/28 , C07C215/14
摘要: Cationic lipid compositions are provided that are useful for efficient delivery of macromolecules, such as nucleic acids, into a wide variety of eukaryotic cell types. Methods for using the compositions also are provided.
摘要翻译: 提供了阳离子脂质组合物,其可用于将大分子如核酸有效递送到各种真核细胞类型中。 还提供了使用组合物的方法。
-
公开(公告)号:US5916838A
公开(公告)日:1999-06-29
申请号:US955264
申请日:1997-10-21
申请人: Joachim Wulff-Doring , Johann-Peter Melder , Gerhard Schulz , Guido Voit , Gutshoven Frank , Wolfgang Harder
发明人: Joachim Wulff-Doring , Johann-Peter Melder , Gerhard Schulz , Guido Voit , Gutshoven Frank , Wolfgang Harder
IPC分类号: B01J23/89 , C07B61/00 , C07C209/02 , C07C209/14 , C07C209/16 , C07C209/26 , C07C211/10 , C07C211/13 , C07C213/02 , C07C215/14 , B01J23/40 , B01J23/46
CPC分类号: C07C209/16 , B01J23/8926 , B01J23/8933
摘要: A catalyst comprises, based on the total weight of the catalyst,0.1-6% by weight of cobalt, nickel or a mixture thereof,0.001-25% by weight of ruthenium,0-10% by weight of copper and0-5% by weight of promoterson a porous metal oxide carrier.It preferably comprises 0.1-3% by weight of cobalt and 0.1-3% by weight of nickel. It can be used in hydrogenation reactions, dehydrogenation reactions or hydrogenation/dehydrogenation reactions, in particular in the amination of alkylene oxides, alcohols, aldehydes or ketones with ammonia or primary or secondary amines.
-
公开(公告)号:US5827538A
公开(公告)日:1998-10-27
申请号:US571980
申请日:1996-01-17
IPC分类号: C07C201/08 , A61K9/00 , A61K9/32 , C07C201/12 , C07C205/11 , C07C205/19 , C07C205/23 , C07C205/26 , C07C205/34 , C07C205/42 , C07C215/14 , C07C271/08 , C07C301/00 , C07C309/67 , C07C309/73 , C07C319/14 , C07C323/16 , C07C323/25 , C07C323/29 , C08G18/38 , C08G59/50 , C08G63/685 , C08L101/00 , C09D163/00 , G03F7/00 , G03F7/004 , G03F7/039 , G03F7/16 , A61K9/24
CPC分类号: C07C205/11 , A61K9/0004 , C07C205/19 , C07C205/26 , C07C215/14 , C07C323/25 , C08G18/384 , C08G59/50 , C08G59/504 , C08G63/6856 , C09D163/00 , G03F7/0045 , G03F7/039 , G03F7/164
摘要: An osmotic device that, following the imbibement of water vapor, provides for the controlled release of a beneficial agent to an aqueous environment. The device comprises a hydrophilic formulation including a beneficial agent, and if needed, an osmagent, surrounded by a wall. The wall is formed at least in part of a semipermeable hydrophobic membrane having an average pore size between about 0.1 .mu.m and 30 .mu.m. The pores are substantially filled with a gas phase. The hydrophobic membrane is permeable to water in the vapor phase and the hydrophobic membrane is impermeable to an aqueous medium at a pressure less than about 100 Pa. The beneficial agent is released, for example, by osmotic pumping or osmotic bursting upon imbibement of sufficient water vapor into the device core. These devices minimize incompatibilities between the beneficial agent and ions (such as hydrogen or hydroxyl) or other dissolved or suspended materials in the aqueous medium, since contact between the beneficial agent and the aqueous medium does not occur until after the beneficial agent is released. This results from the semipermeable membrane's selective permeability for water vapor. In addition, the high water fluxes attendant with these vapor-permeable membranes facilitate the delivery of beneficial agents having low solubilities, and the delivery of high dosages of beneficial agents.
摘要翻译: PCT No.PCT / IB94 / 00114 Sec。 371日期1996年1月17日 102(e)日期1996年1月17日PCT 1994年5月19日PCT PCT。 公开号WO95 / 03033 日期1995年2月2日渗透装置在水蒸汽吸收之后提供有益剂控制释放到含水环境中。 该装置包括亲水性制剂,其包括有益剂,并且如果需要,包含被壁围绕的渗透剂。 所述壁至少部分形成有平均孔径在约0.1μm至30μm之间的半透性疏水膜。 孔基本上充满气相。 疏水膜在气相中是透水的,并且疏水膜在低于约100Pa的压力下对水介质是不可渗透的。有益剂例如通过渗透泵送或渗透的足够的水渗透渗出来释放 蒸汽进入设备核心。 这些装置使有益剂和离子(例如氢或羟基)或水性介质中的其它溶解或悬浮物质之间的不兼容性最小化,因为有益剂和水性介质之间的接触直到有益剂被释放才会发生。 这是由半透膜对水蒸汽的选择性渗透性产生的。 此外,伴随这些透气膜的高水通量促进了具有低溶解度的有益试剂的递送和高剂量的有益试剂的输送。
-
公开(公告)号:US5744644A
公开(公告)日:1998-04-28
申请号:US652148
申请日:1996-05-23
申请人: Bernd Papenfuhs
发明人: Bernd Papenfuhs
IPC分类号: C07C215/14 , C07C211/03
CPC分类号: C07C215/14
摘要: It has been found that certain polyhydroxyalkylamines have a particularly good solubility in water, alcohols and in mixtures of water and alcohols. The concentrated solutions described consist essentially of water, alcohols, preferably C.sub.1 -C.sub.3 -alcohols, or water/alcohol mixtures as solvent and at least one dialkylaminopropylglucamine of the formula 1 below Z--NH--CH.sub.2 CH.sub.2 CH.sub.2 --NR.sup.1 R.sup.2 ( 1) where R.sup.1 and R.sup.2 are identical or different and are C.sub.1 -C.sub.4 -alkyl or hydroxyalkyl having from 2 to 4 carbon atoms and Z is a linear polyhydroxyhydrocarbon radical having at least three OH groups which may, if desired, be alkoxylated, The concentrated solutions are particularly useful for preparing the corresponding polyhydroxyalkylcarboxamides.
摘要翻译: 已经发现,某些多羟基烷基胺在水,醇和水和醇的混合物中具有特别好的溶解性。 所描述的浓缩溶液基本上由水,醇,优选C 1 -C 3醇或作为溶剂的水/醇混合物和至少一种下式Z-NH-CH 2 CH 2 CH 2 -NR 1 R 2(1)的二烷基氨基丙基葡糖胺组成,其中R 1和R 2是 相同或不同的是具有2至4个碳原子的C 1 -C 4 - 烷基或羟烷基,Z是具有至少三个OH基团的直链多羟基烃基团,如果需要,其可以被烷氧基化。浓缩溶液特别可用于制备 相应的多羟基烷基酰胺。
-
-
-
-
-
-
-
-
-